A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Manier, S.; Lambert, J.; Macro, M.; Chalopin, T.; Dib, M.; Rumpler, Anne; Gay, J.; Bastie, J.; Jacquet, C.; Sonntag Mottier, Cecile; Vincent, L.; Perrot, A.; Mariette, C.; Montes, Lydia; Rigaudeau, S.; Bigot, N.; Doyle, M.; Santra, D.; Smirnov, P.; Albrecht, C.; Touzeau, C.; Corre, J.; Moreau, P.; Avet-Loiseau, Hervé; Hulin, C.; Leleu, X.; Facon, T.

doi:10.1182/blood-2025-367

Public

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Shared by NobleBlocks on Nov 3, 2025 • 12:00 AM UTC

Authors:

S. Manier

J. Lambert

M. Macro

Abstract

Background. Teclistamab is a subcutaneous bispecific IgG4 antibody targeting BCMA on myeloma cells and CD3 on T cells, enabling T-cell–mediated cytotoxicity. Daratumumab is an anti-CD38 monoclonal antibody used in combination with standard agents. The current standard-of-care regimens in elder...

Discussions